Belgium· BE-AMP-SAM471502-00
Amitiza 24 µg
A lubiprostone product containing lubiprostone, registered in Belgium by Takeda Belgium. The same ATC class is registered in 4 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lubiprostone is registered in 4 of 19 countries.
Countries holding a registration under ATC A06AX03 (lubiprostone), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Lubiprostone · ATC A06AX03
4 / 19 countries
- Belgiumprice
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lubiprostone
- Manufacturer
- Takeda Belgium
- Country
- Belgium (BE)
- ATC code
- A06AX03
- ATC class
- Lubiprostone
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for lubiprostone.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lubiprostone · interactions on record
2 records
- 2 moderate
Most severe, free to view
- IdelalisibL01EM01moderate
- IdelalisibL01XX47moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lubiprostone in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/72cccc30-30a2-42bb-9a7f-54c6aac0b32f GET /v1/drugs/72cccc30-30a2-42bb-9a7f-54c6aac0b32f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, soft",
"source": "afmps",
"status": "REVOKED",
"name_en": "Amitiza 24 µg",
"name_fr": "Amitiza 24 µg",
"name_nl": "Amitiza 24 µg",
"amp_code": "SAM471502-00",
"strengths": [
"0.0240"
],
"pack_count": 2,
"substances": [
"Lubiprostone"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lubiprostone",
"authorisation_numbers": [
"BE471502"
]
}See everything about lubiprostone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.